Results 1 to 10 of about 5,430 (118)
Fast-acting insulin aspart - from insulin portraits to patient portraits
Медицинский совет, 2021 Postprandial hyperglycemia is an independent risk factor for cardiovascular disease (CVD). Bolus insulins aim to mimic the physiological action of endogenous insulin secreted in response to food intake to control peaks of postprandial glycemia (PPG ...
T. Yu. Demidova, M. Ya. Izmaylova
doaj +1 more source
A Comparison of the Efficacy of Insulin Aspart and Regular Insulin for Managing Gestational Diabetes and their Effects on Delivery Outcomes [PDF]
Journal of Midwifery & Reproductive Health, 2021 Background & aim: Rapid-acting insulin analogs, such as insulin aspart, are used in type 1 and type 2 diabetes in pregnancy, and are approved for using in gestational diabetes mellitus (GDM).
Parichehr Pooransari +3 more
doaj +1 more source
Сахарный диабет, 2020 Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously ...
Hanne Haahr, Tim Heise
doaj +1 more source
Journal of the Formosan Medical Association, 2019 Although hypersensitivity reaction to insulin was supposed to be less-frequent with current insulin analogue, case reports with different types of allergic reactions to insulin analogue were still reported. The most common form is type I hypersensitivity
Wei-Lun Wen +6 more
doaj +1 more source
Therapeutic Advances in Endocrinology and Metabolism, 2018 Background: Fast-acting insulin aspart is a new formulation of the rapid-acting insulin analogue insulin aspart and represents an advancement over current rapid-acting insulin analogues in terms of onset of action and postprandial glucose control.
Lalantha Leelarathna +3 more
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, is a multicentric (28 countries), 24-weeks, non-interventional study to evaluate the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical ...
Wiam Ibrahim Hussein, Noha Taha
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
R Santosh, Ravi Mehrotra, N G Sastry
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Issam M Hajjaji +5 more
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Ahmed Farouqi, Asmae Chadli
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
S Nallaperumal, Johny Kannampilly
doaj +1 more source